Literature DB >> 16805752

Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.

A Yaren1, I Oztop, A Kargi, C Ulukus, A Onen, A Sanli, O Binicier, U Yilmaz, M Alakavuklar.   

Abstract

In non-small-cell lung cancer (NSCLC), stage of the disease is still the most important prognostic factor. Other than stage, many biological markers and many other prognostic factors are studied to define their effects on prognosis of lung cancer. In this study, we aimed to evaluate the expressions of Bax and bcl-2 genes which are important in apoptosis and c-kit, which is a tyrosine kinase transmembrane receptor, as well as searched their response to treatment modalities and effects on survival. Sixty-nine NSCLC cases' pathological samples were stained with specific Bax, bcl-2 and c-kit dyes by immunohistochemical (IHC) methods. IHC evaluation was done by the semichantitative method according to the distribution and intensity of the staining. Twelve of 69 cases (17.4%) were stage I, 28 (40.5%) were stage II, 17 were (24.6%) stage IIIA, nine cases were (13.1%) stage IIIB and three cases (4.4%) were stage IV patients. Their histological subtypes were as follows: of 69 cases, 36 (52.2%) were squamous cell carcinoma, 28 (40.6%) were adenocarcinoma, five (7.2%) were adenosquamous cell carcinoma (two patients) and large-cell carcinoma (three patients). The positive immunostaining rates for Bax and bcl-2 in whole group, squamous cell carcinoma and adenocarcinoma groups were 40.6%/36.2%, 55.6/69.4% and 25.0/0.0%, respectively. The positive immune staining rates for c-kit in whole group, squamous cell carcinoma and adenocarcinoma groups were 7.2, 5.6 and 7.1%, respectively. We didn't find any correlation with Bax, bcl-2 and c-kit expressions and clinicopathological parameters such as age, tumour size, lymph node involvement, smoking, stage of the disease, response to radiotherapy and chemotherapy. Results are interpreted according to survival; bax and bcl-2 expressions were not so effective both in whole group and histologically subgrouped patients. C-kit expression was also found not related with survival in whole group whereas found as a bad prognostic factor in patients with squamous cell carcinoma. These findings could indicate that the expression of apoptotic pathway markers and c-kit may have a role in the prognosis of early stage NSCLC, especially with squamous cell carcinoma subtype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16805752     DOI: 10.1111/j.1368-5031.2006.00742.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  15 in total

1.  KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.

Authors:  Ling Zhao; Jan J Melenhorst; Lemlem Alemu; Martha Kirby; Stacie Anderson; Maggie Kench; Shelley Hoogstraten-Miller; Lauren Brinster; Yasuhiko Kamikubo; D Gary Gilliland; P Paul Liu
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk.

Authors:  Jie Lin; Charles Lu; David J Stewart; Jian Gu; Maosheng Huang; David W Chang; Scott M Lippman; Xifeng Wu
Journal:  Carcinogenesis       Date:  2012-06-04       Impact factor: 4.944

3.  Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

Authors:  Faye M Johnson; B Nebiyou Bekele; Lei Feng; Ignacio Wistuba; Xi Ming Tang; Hai T Tran; Jeremy J Erasmus; Li-Ling Hwang; Naoko Takebe; George R Blumenschein; Scott M Lippman; David J Stewart
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

Review 4.  Prediction of Genes Involved in Lung Cancer with a Systems Biology Approach Based on Comprehensive Gene Information.

Authors:  Shahram Parvin; Hamid Sedighian; Ehsan Sohrabi; Mahdieh Mahboobi; Milad Rezaei; Dariush Ghasemi; Ehsan Rezaei
Journal:  Biochem Genet       Date:  2021-12-02       Impact factor: 2.220

5.  High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.

Authors:  Valsamo K Anagnostou; Frank J Lowery; Vassiliki Zolota; Vassiliki Tzelepi; Arun Gopinath; Camil Liceaga; Nikolaos Panagopoulos; Konstantina Frangia; Lynn Tanoue; Daniel Boffa; Scott Gettinger; Frank Detterbeck; Robert J Homer; Dimitrios Dougenis; David L Rimm; Konstantinos N Syrigos
Journal:  BMC Cancer       Date:  2010-05-09       Impact factor: 4.430

Review 6.  Apoptosis block as a barrier to effective therapy in non small cell lung cancer.

Authors:  Ian Paul; J Mark Jones
Journal:  World J Clin Oncol       Date:  2014-10-10

7.  Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors.

Authors:  Svjetlana Radović; Mirsad Babić; Mirsad Dorić; Ajna Hukić; Suada Kuskunović; Ademir Hadzismajlović; Fadila Serdarević
Journal:  Bosn J Basic Med Sci       Date:  2007-08       Impact factor: 3.363

8.  Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer.

Authors:  I Paul; A D Chacko; I Stasik; S Busacca; N Crawford; F McCoy; N McTavish; B Wilson; M Barr; K J O'Byrne; D B Longley; D A Fennell
Journal:  Cell Death Dis       Date:  2012-12-20       Impact factor: 8.469

9.  Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology.

Authors:  Seong Hyun Jeong; Hyun-Woo Lee; Jae Ho Han; Seok Yun Kang; Jin-Hyuk Choi; Youn Mu Jung; Ho Choi; Young Taek Oh; Kwang Joo Park; Sung Chul Hwang; Seung Soo Sheen; Yoon Jung Oh; Jang Hee Kim; Ho-Yeong Lim
Journal:  Jpn J Clin Oncol       Date:  2008-09-04       Impact factor: 3.019

10.  Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review.

Authors:  Jie Zhang; Shengfei Wang; Lei Wang; Rui Wang; Sufeng Chen; Bin Pan; Yihua Sun; Haiquan Chen
Journal:  Onco Targets Ther       Date:  2015-11-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.